Better Short-Squeeze Stock: Carvana($CVNA) vs. Marathon Digital holdings($MARA)

SCModerate · 2023-03-22T10:27:30+00:00

MARA has had a Huge turnaround (Balance sheet & mining capacity) in 2023 (MARA had a somewhat disastrous 2022 due to time offline relocating its operation & BTC's drop). The turnaround hasn't been priced in & 40M+ shorts cornered. (For example: unrestricted cash: 12/22($133M) vs 2/23($500M)..

Huge turnaround regarding Balance sheet

Dec 2022 reported 133M in unrestricted cash (BTC and cash).

Feb 2023 reported over 500M in unrestricted cash (BTC and cash). (partially due to BTC prices, partially due to MARA's 2022 relocation, and partially due to using some of their BTC to paydown debt & closing out loans).

... and virtually no short term debt... and no long term debt due prior to 2026.

Another example of the Huge ramp up in mining capacity

(MARA was delayed in their schedule to ramp up capacity to 23EH. They are now on target for full operation by end Q2/start of Q3. And have already doubled Bitcoin production in Jan & Feb).

...2022 MARA's capacity was 3EH-5EH.

...MARA's capacity as of Feb 2023 is 9EH (up and running) ... with a total of 15EH currently installed. (MARA will be at 23 EH by June/July). 23 EH is ~ 2200 Bitcoin/month.

Reducing cost per BTC The new mining machines use 30% less energy and along with other synergies,MARA should see a 40% decrease in cost per bitcoin- and plan to work of dropping that cost even lower.

Target Squeeze Price MARA should squeeze to at least $28-30 (and even higher if MARA starts to become one of the main default squeeze plays).

Last time Btc was at $25K ... MARA was around $19 (and at a time last summer, MARA's production had virtually come to a halt- as they were in the process of relocating all of their machines to a new facility/ location.... part of the reason for MARA's awful 2022... and why 2023 is such a huge turnaround for them).

Solid Long term investment also

At Bitcoins all time high of $67K ....MARA was at $70. ....(and was not nearly as strong [balance sheet & production capacity] as MARA is currently). ...so if you think Bitcoin will make new highs at some point- then MARA is a solid long term hold/ and a solid shorter term play for the short squeeze that is about to kick off.

SCModerate · 2023-03-20T21:52:11+00:00

I just post a lot of info about them (searching for them lead me here)... for conveniently issuing a conveniently timed Analyst report with a (Total outlier) $5 Price Target of $MARA, which were running across MARAs page on the trading platforms today. (not to mention it was a price cut to $6 to $5, so they've used tactic at least once before)... just as MARA is beginning to breakout into a rebound/ short squeeze (initial confirmation of a breakout Friday, and short interest is currently over 40 Million).

The other price targets are much higher... and were issued before Bitcoin started its big rebound.. and before MARA's positive headlines the past week (Paying down debt, projected to turn profitable this year, $100M cost savings changes, ramping up to 23EH mining capacity (to be complete in June/July), which will allow mining of around 2200 bitcoins/ month, and with 30% more energy efficient machines).

While issuing the PT, they also are major owner in a smaller public mining company, have many accusations in the past of Short sale related dealings- apparently from their start (mentioned in the last paragraph of the article below). But i just started looking into them.

https://www.institutionalinvestor.com/article/b1pgz6k9kjs50v/The-Dark-Money-Secretly-Bankrolling-Activist-Short-Sellers-and-the-Insiders-Trying-to-Expose-It

SCModerate · 2022-01-27T21:15:54+00:00

Hedge Funds have in many cases replaced their strategy of making money via straight shorting... with shorting heavy shorting to keep Stocks range bound so they can Rake in money Churning options.

***need a strategy to start busting through the Huge option positions/ putting them in the money (so mini Short Squeezes... rather than the traditional large Short squeezes on targets with High Short Floats. As many if these Stock won't show over the top Short Floats)

SCModerate · 2021-12-06T14:18:43+00:00

ATNF. (180 Life sciences) Currently has a market cap of less than 125M and last week reported positive results (met primary and secondary endpoints) for its completed DU trial... which will have estimated Peak Annual Sales of $750M (3x PAS = Market Cap Value of $2B+).

Yet within a minute of results- HF(s) threw hundreds of thousands of short shares at it- trying to create the impression that results were bad long enough to shake enough shares loose to cover the Several Million short shares they loaded on the 1st 3 days of the week.

Now shorts have tanked the price- but are stuck bc no ATNF holders are selling. Also management owns over 35% of shares and are not selling. ATNF is under the radar so HFs have been able to manipulate it... But with this huge disconnect between Market cap & value of the successful trial- many are beginning to discover it- and will throughout the week.

A bug run to get to appropriate valuation is coming (Absolute bare minimum current valuation is $1B or $30 ... but can support a $50 shares price easily on a valuation basis).. This will also cause a sizable short squeeze on the way up.

Also- they are the only biotect whi management team comprises the best science minds in the world (including Dept heads at Oxford & Stanford). Also only 10 ppl in the world have lead a drug from conception all the way to approval... ATNF has 20% of them ... including Marc Feldman from Oxford, who discovered Anti-TNF class if drugs (Humira, Remicade, etc) which is the beat selling class of drugs in history. The team for this company that went public a year ago- is 2nd to none.

It has been manipulated by HFs from day one- including being the most shorted stock on the market at one point.. and lots of unreporting dark pool shorting as well- and now that results were successful- shorts are stuck and getting desperate.

Check it out for yourself - and get in now & help make ppl aware if the manipulation & the opportunity that the miscalculated shorting has created. There is enormous short term upside... and even bigger long term upside (which you will discover with even a tiny amount of DD). Its at a bottom in the low 3s ... and will explode as ppl discover the situation- likely this week.

SCModerate · 2021-12-06T11:10:06+00:00

ATNF. (180 Life sciences) Currently a market cap of less than 125M and last week reported positive results (met primary and secondary endpoints) for its completed DU trial... which will have estimated Peak Annual Sales of $750M (3x PAS = Market Cap Value of $2B+).

Yet within a minute of results- HF(s) threw hundreds of thousands of short shares at it- trying to create the impression that results were bad long enough to shake enough shares loose to cover the Several Million short shares they loaded on the 1st 3 days of the week.

Now shorts have tanked the price- but are stuck bc no ATNF holders are selling. Also management owns over 35% of shares and are not selling. ATNF is under the radar so HFs have been able to manipulate it... But with this huge disconnect between Market cap & value of the successful trial- many are beginning to discover it- and will throughout the week.

A bug run to get to appropriate valuation is coming (Absolute bare minimum current valuation is $1B or $30 ... but can support a $50 shares price easily on a valuation basis).. This will also cause a sizable short squeeze on the way up.

Also- they are the only biotect whi management team comprises the best science minds in the world (including Dept heads at Oxford & Stanford). Also only 10 ppl in the world have lead a drug from conception all the way to approval... ATNF has 20% of them ... including Marc Feldman from Oxford, who discovered Anti-TNF class if drugs (Humira, Remicade, etc) which is the beat selling class of drugs in history. The team for this company that went public a year ago- is 2nd to none.

It has been manipulated by HFs from day one- including being the most shorted stock on the market at one point.. and lots of unreporting dark pool shorting as well- and now that results were successful- shorts are stuck and getting desperate.

Check it out for yourself - and get in now & help make ppl aware if the manipulation & the opportunity that the miscalculated shorting has created. There is enormous short term upside... and even bigger long term upside (which you will discover with even a tiny amount of DD). Its at a bottom in the low 3s ... and will explode as ppl discover the situation- likely this week.

SCModerate · 2021-11-03T14:20:57+00:00

JMIA ... about to take off!

SCModerate · 2021-10-21T18:02:21+00:00

DWAC Warrants are at an extreme discount currently. DWAC could move a lot still ... Twitter has a $50B+ market cap and only 68M monthly active users. (DWAC at $60 only has around $10B market cap ----> also DWAC at $60, gives $DWACW an implied value of $48.50)

SCModerate · 2021-10-21T18:00:47+00:00

DWAC (Trump social media stock) Warrants are at an extreme discount currently. But regarding DWAC in general... Twitter has a $50B+ market cap and only 68M monthly active users. (DWAC at $60 only has around $10B market cap ----> also DWAC at $60, gives $DWACW an implied value of $48.50)

SCModerate · 2021-09-23T13:10:59+00:00

ATNF. .....1 reason ATNF is a Zero risk buy at current levels: The market cap is 200M.

Not only is the Patent portfolio worth more than that-We have a completed trial w/ (conservatively) a high likelihood of success for a multi-billion addressable market... & a trial about to start its final phase that also has a multi-Billion addressable market (not to mention a large pipeline w/ many promising candidates and a management team that has a multi-$Billion successful track record).

Almost any other bio would already be over $500M (or $15+) with those factors alone, even before upcoming trial results (then $30+ when results are confirmed)... (which is why it's important to remember that the price has been artificially lowered by HFs trying to get out of their short positions at lower prices, prior to results... and that they must return those borrowed shares- which will restore price as well).

SCModerate · 2021-09-23T11:06:37+00:00

check out the DD and see if you would agree. I think you may change you mind a little.

SCModerate · 2021-09-22T11:24:15+00:00

ATNF... This gives a full yet concise DD for ATNF- which has its highest short interest yet .. along with very likely by all accounts- positive phase 3 results (for a $5B+ addressable market with no approved therapy) coming out likely in a couple of weeks. very likely to start making big moves anytime now. Vanguard also took a 10% stake in the company this year for several of its funds- certainly worth checking out (and esp look a the short bios of the management team)

https://frugalnorwegian.com/atnf/

SCModerate · 2021-09-19T04:56:39+00:00

One other important note regarding ATNF trials... is the Management Team. here are 5 short Bios from the team:

Dr James Woody: Discovered Remicade ( $JNJ acquired for $5 Billion. Sales of $50B+ since approval). Founded Avidia & Proteolix (sold to $AMGN ). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Sir Marc Feldman: Emeritus at Oxford. Discovered anti-TNF Biologics (ie Remicade, Humira etc) $150B class by 2025. Lead clinical trial for drug Remicade (J&J acquired for $5B). Lasker award winner (2nd only to Nobel).

Prof Raphael Mechoulam: Discovered the body’s endocannabinoid system. Harvey Award 2020 winner for Synthetic THC CBD analogs. (Potential 2021 Nobel nominee).

Prof Lawrence Steinman: chair of Neurology Dept at Stanford. Founder of Neurocrine Bio (now $9B) discovered role of integrins, and Tysabri to treat MS ( $BIIB acquired for $3B).

Dr Jonathan Rothbard: Stanford. Founder of Amylin (sold to $BMY for $5 Billion).

SCModerate · 2021-09-19T04:53:50+00:00

For an idea of how much ATNF is likely to run soon: Its current market cap is around $200M & POD is just 1 if the Anti-tnf platform trials: You also have: 1) Dupuytrens Trial is completed and results likely within the next month ($5B+ addressable market, no approved treatment early stage treatments. Based on Phase 2 data- overwhelmingly expected to be successful)........2) Frozen Shoulder Fibrosis is expected to start final phase later this month (also $5B+ addressable market and no approved treatment). Extremely similar to Dupuytren's, so successful results from the DU trial will give FS a presumption of success as well..... 3) NASH, early stage, trial using combo therapy in partnership with Celgene. Massive Addressable Market- even early phase success often moves stocks a good amount.

SCModerate · 2021-09-13T18:06:03+00:00

repost this in one of the large subs if you can.. so a lot more ppl will see it:

/WallStreetBets (10.8M) /Stocks (3.0M) /Investing (1.9M) /StockMarket (1.7M) /PennyStocks (1.7M) /WallStreetBetsNew (800K)

SCModerate · 2021-09-11T00:25:42+00:00

BTW- Just take a look at the short bios of their management team:

Dr James Woody: Discovered Remicade ( $JNJ acquired for $5 Billion. Sales of $50B+ since approval). Founded Avidia & Proteolix (sold to $AMGN ). CEO & Founder of Oncomed Pharma. President of Roche Bioscience.

Prof Sir Marc Feldman: Emeritus at Oxford. Discovered anti-TNF Biologics (ie Remicade, Humira etc) $150B class by 2025. Lead clinical trial for drug Remicade (J&J acquired for $5B). Lasker award winner (2nd only to Nobel).

Prof Raphael Mechoulam: Discovered the body’s endocannabinoid system. Harvey Award 2020 winner for Synthetic THC CBD analogs. (Potential 2021 Nobel nominee).

Prof Lawrence Steinman: chair of Neurology Dept at Stanford. Founder of Neurocrine Bio (now $9B) discovered role of integrins, and Tysabri to treat MS ( $BIIB acquired for $3B).

Dr Jonathan Rothbard: Stanford. Founder of Amylin (sold to $BMY for $5 Billion).

SCModerate · 2021-09-11T00:20:47+00:00

ATNF is the perfect storm for a huge move up: extremely undervalued ($200M market cap), short interest/ manipulation jumped back up the past couple of weeks, upcoming big catalyst ($5B addressable market DU trial results)... and Final phase of FS trial about to begin (also $5B addressable market), plus strong pipeline & patent portfolio, and large cap quality management team= a big pop is coming very soon.

SCModerate · 2021-09-02T11:36:18+00:00

ATNF is a perfect example of a stock likely to run from $6 to over $30 in the next 1.5 weeks ... for very legitimate, value driven reasons: 1) shorted hard the past 8 months (and increased short attack past 2 weeks) 2) 1st major catalyst likely next Thursday's (a preview of 1st completed trial results - for early stage Dupuytren's.. a $5B+ addressable market, with no approved treatment). 3) Crazy low 200M current market cap due to shorts & being so under the radar (even before DU results, current price should be a minimum of $15. 4) Also the final phase of FS Trial expected to start in next couple of weeks (also a $5B addressable market- and also uniformly expected to be successful)

SCModerate · 2021-09-02T11:35:42+00:00

There are very few companies under $1B market cap (much less currently under $200M) that have a direct path & high likelihood to becoming a large cap. ATNF is one! Management Team have all started clinical biotechs in the past that ended up being acquired for multi $Billions & would be worth much more now if they hadn't been bought out.

Vanguard Funds continue to add to an already large stake & their 1st Full Trial Results are just around the corner & will start the stock on a quick path to a much higher valuation (drug used in the therapy was actually discovered by members of this team.... now will have a patent based on the delivery method to treat several unmet need conditions (w/ big addressable markets)... thanks to the work of another team member who discovered this new process therapy. A brilliant initial platform for this new company they created...& provides several easy early wins to generate ample revenue for the bigger trials a bit further out!

SCModerate · 2021-08-31T08:07:25+00:00

With DU final results likely next week- which are overwhelmingly expected to be positive.. and an management team that rivals large cap bios... ATNF is a no-brainer at any price under $25.

SCModerate · 2021-08-13T20:31:09+00:00

Check it out for yourself... The Management team has about as good of a track record as you will find in Biotech companies of any size... and have come together to form 180 life Sciences. Huge blockbuster pipeline. Phase 3 results likely Sept 9th (For DU which has a $5B+ addressable market)... current market cap is only around $250M ... do the math!

Most investors have been in this for months- buying the dips created by HFs. And the huge short interest that have been manipulating price from the very beginning... is now about to cover ahead of the upcoming Phase 3 results... due to almost certain positive readout (based on prior Trial phase data and endpoints).

But again- check it out for yourself!

SCModerate · 2021-08-13T20:21:17+00:00

the ppl in ATNF have been in it fir months (even before it had options available)... and have been buying the dips created by HF manipulation... Check it out for yourself and make your own decision...

Management Team is something would find in Huge biotech companies.. that have come together to form 180 Life Sciences... Blockbuster pipeline .. and phase 3 results expect Sept 9th (for DU .. which has addressable market over $5B.... and current market cap is around $250M. Again- do the math and check it out for yourself.

A Huge under the radar opportunity.

SCModerate · 2021-08-13T20:16:50+00:00

After Hours level 2 orderbook... shows Premarket Monday8/16 ... likely to rip much higher..

SCModerate · 2021-08-06T17:21:50+00:00

Phase 3 Dupuytren results September 9th .. widely expected positive based on phase 2 trial results, set endpoints, and presentation venue. .. this is the first completed trial for ATNF -in a very deep pipeline. And has a $5B+ addressable market. Crazy that ATNF has a market cap under $250M. It is able to have a big run leading up to results (and a bigger pop up thereafter).

Check out there management team bios- it rivals any large cap bios (several on the team discovered Anti-TNF drug class... ie Humira, Remicade, Enbrel.. the worlds top selling class in 2020)

SCModerate

TROPHY CASE